TY - JOUR T1 - Analysis: The potential health and economic impact of dexamethasone treatment for patients with COVID-19 JF - medRxiv DO - 10.1101/2020.07.29.20164269 SP - 2020.07.29.20164269 AU - Ricardo Águas AU - Adam Mahdi AU - Rima Shretta AU - Peter Horby AU - Martin Landray AU - Lisa White AU - the CoMo Consortium Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/30/2020.07.29.20164269.abstract N2 - Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment would be rolled out in the UK and globally, as well as its cost-effectiveness of implementing this intervention. We estimate that, for the UK, approximately 12,000 [4,250 - 27,000] lives could be saved by January 2021. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 [240,000 - 1,400,000] lives saved globally. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, e.g. in low and middle-income countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the COVID-19 Research Response Fund, managed by the Medical Sciences Division, University of Oxford. LJW is supported by the Li Ka Shing Foundation. RA acknowledges funding from the Bill and Melinda Gates Foundation (OPP1193472).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:secondary data analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall used data is oublicly available ER -